In the phase II trial RTOG1205, Reirradiation (re-RT) with concurrent bevacizumab (BEV) demonstrated a clinically meaningful improvement in PFS in...

In the updated analysis of phase III RESONATE-2 trial, treatment with BTK inhibitor (#ibrutinib) for at least 5 years showed...

In the randomized phase III TOPIC-NEC trial, Etoposide and cisplatin (EP) showed comparable efficacy to irinotecan and cisplatin (IE) as...

Although #colonoscopy is widely used as a #screening test to detect colorectal cancer (#CRC), it is more invasive and resources...

On November 10, 2022, the FDA approved #tremelimumab in combination with #durvalumab and platinum-based chemotherapy as first line therapy for...

In phase III TRIPLETE Study by GONO group, the intensification of the upfront chemotherapy backbone in combination with #panitumumab did...

In a Chinese trial published in JAMA oncology, the addition of adjuvant #capecitabine improved failure-free survival (FFS) among patients with...

In a large Propensity score matched retrospective study was conducted to assess the value of systemic Therapy and radiation therapy...

In a study published in the Annals of surgical oncology journal, further axillary lymph node dissection (ALND) failed to improve...

In phase II ECOG-ACRIN E2211 trial, the addition of Capecitabine to Temozolomide significantly improved the progression-free survival (PFS) in patients...